Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Docetaxel

FDA-approved product (injectable, injection), marketed as Beizray, Docefrez, Docetaxel and 2 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Docetaxel
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Adenocarcinoma
  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Cancer
  • Gastric adenocarcinoma
  • Gastric cancer
  • Gastric carcinoma
  • Gastroesophageal junction adenocarcinoma
  • Head and neck carcinoma
  • Head and neck malignant neoplasia
  • Head and neck neoplasia
  • Head and neck squamous cell carcinoma
  • Malignant tumor of neck
  • Metastatic prostate cancer
  • Neoplasm
  • and 6 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Taxanes
FDA pharmacologic class
Microtubule Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA57.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli45.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae34.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis50.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Docetaxel in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Docetaxel with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Registry for Patients Treated on the Clinical Trial TAX 3503

    NCT01813370 · start 2013-03

    Registered record
    Registry ID
    NCT01813370
    Conditions
    Prostate Cancer
    Interventions
    No intervention
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2013-03
    Completion
    2022-03-04
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionNo intervention
    PhaseNot recorded
    Registry statusCompleted

  • Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer.

    NCT01298193 · start 2011-05

    Registered record
    Registry ID
    NCT01298193
    Conditions
    Breast Cancer
    Interventions
    Aprepitant
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-05
    Completion
    2014-04
    Enrolment
    212

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionAprepitant
    PhasePhase 4
    Registry statusCompleted

  • Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer

    NCT01359397 · start 2011-03

    Registered record
    Registry ID
    NCT01359397
    Conditions
    Metastatic Gastric Cancer; Adenocarcinoma of the Gastro-oesophageal Junction
    Interventions
    Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab; Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Trastuzumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2011-03
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Gastric Cancer; Adenocarcinoma of the Gastro-oesophageal Junction
    InterventionDocetaxel, Oxaliplatin, Capecitabin, Bevacizumab; Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Trastuzumab
    PhasePhase 2
    Registry statusUnknown

  • Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen

    NCT01254279 · start 2010-12

    Registered record
    Registry ID
    NCT01254279
    Conditions
    Prostate Cancer Metastatic
    Interventions
    CABAZITAXEL
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-12
    Completion
    2014-12
    Enrolment
    984

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer Metastatic
    InterventionCABAZITAXEL
    PhasePhase 3
    Registry statusCompleted

  • Preoperative Chemoradiotherapy Versus Chemotherapy Alone in Nonsmall Cell Lung Cancer (NSCLC) Patients With Mediastinal Lymph Node Metastases

    NCT01187290 · start 2010-08

    Registered record
    Registry ID
    NCT01187290
    Conditions
    Non-small Cell Lung Cancer
    Interventions
    neoadjuvant chemoradiotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2010-08
    Completion
    2013-06
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer
    Interventionneoadjuvant chemoradiotherapy
    PhasePhase 2
    Registry statusUnknown

  • Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC)

    NCT01126138 · start 2010-07

    Registered record
    Registry ID
    NCT01126138
    Conditions
    Carcinoma, Invasive Ductal, Breast
    Interventions
    Vinorelbine plus Capecitabine for 6 cycles, followed by Capecitabine; Docetaxel plus Capecitabine for 6 cycles, followed by Capecitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2010-07
    Completion
    2015-08
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Invasive Ductal, Breast
    InterventionVinorelbine plus Capecitabine for 6 cycles, followed by Capecitabine; Docetaxel plus Capecitabine for 6 cycles, followed by Capecitabine
    PhasePhase 3
    Registry statusUnknown

  • Hematologic Toxicity Observation of the Docetaxel+ Cisplatin+ Fluorouracil (TPF)Medical Protocol

    NCT01268878 · start 2010-06

    Registered record
    Registry ID
    NCT01268878
    Conditions
    Squamous Cell Head and Neck Carcinoma
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-06
    Completion
    2011-11
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSquamous Cell Head and Neck Carcinoma
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer

    NCT00976989 · start 2009-11

    Registered record
    Registry ID
    NCT00976989
    Conditions
    Breast Cancer
    Interventions
    Pertuzumab; Trastuzumab; FEC; Docetaxel; TCH
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-11
    Completion
    2016-01
    Enrolment
    225

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionPertuzumab; Trastuzumab; FEC; Docetaxel +1 more
    PhasePhase 2
    Registry statusCompleted

  • Phase III Trial of High Dose vs. Standard Dose Vit D2 With Docetaxel in Met Breast ca

    NCT00944424 · start 2009-07

    Registered record
    Registry ID
    NCT00944424
    Conditions
    Breast Cancer
    Interventions
    Docetaxel + High dose Vitamin D2; Docetaxel + Standard dose Vitamin D2
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2009-07
    Completion
    2012-07
    Enrolment
    260

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionDocetaxel + High dose Vitamin D2; Docetaxel + Standard dose Vitamin D2
    PhasePhase 3
    Registry statusUnknown

  • Everolimus and Docetaxel in Treating Patients With Recurrent, Locally Advanced, or Metastatic Head and Neck Cancer

    NCT01313390 · start 2009-06

    Registered record
    Registry ID
    NCT01313390
    Conditions
    Head and Neck Cancer
    Interventions
    docetaxel; everolimus; laboratory biomarker analysis; pharmacological study
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2009-06
    Completion
    2011-04
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHead and Neck Cancer
    Interventiondocetaxel; everolimus; laboratory biomarker analysis; pharmacological study
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer

    NCT00637897 · start 2008-03

    Registered record
    Registry ID
    NCT00637897
    Conditions
    Breast Cancer
    Interventions
    docetaxel; ixabepilone; paclitaxel; paclitaxel albumin-stabilized nanoparticle formulation; paricalcitol
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-03
    Completion
    2013-03
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventiondocetaxel; ixabepilone; paclitaxel; paclitaxel albumin-stabilized nanoparticle formulation +1 more
    PhasePhase 1
    Registry statusCompleted

  • Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck

    NCT01086826 · start 2008-03

    Registered record
    Registry ID
    NCT01086826
    Conditions
    Head and Neck Squamous Cell Carcinoma
    Interventions
    RT+CDDP/5-FU; RT+CETUXIMAB; INDUCTION CTx(TPF)+(RT+CDDP/5-FU); INDUCTION CTx(TPF)+(RT+CETUXIMAB)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-03
    Completion
    2014-12
    Enrolment
    320

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHead and Neck Squamous Cell Carcinoma
    InterventionRT+CDDP/5-FU; RT+CETUXIMAB; INDUCTION CTx(TPF)+(RT+CDDP/5-FU); INDUCTION CTx(TPF)+(RT+CETUXIMAB)
    PhasePhase 3
    Registry statusCompleted

  • Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.

    NCT00565227 · start 2007-04

    Registered record
    Registry ID
    NCT00565227
    Conditions
    Non-Small-Cell Lung Carcinoma; Prostate Cancer; Bladder Cancer; Urothelial Carcinoma
    Interventions
    vorinostat (suberoylanilide hydroxamic acid); docetaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2007-04
    Completion
    2009-09
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small-Cell Lung Carcinoma; Prostate Cancer; Bladder Cancer; Urothelial Carcinoma
    Interventionvorinostat (suberoylanilide hydroxamic acid); docetaxel
    PhasePhase 1
    Registry statusTerminated

  • Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery

    NCT00408408 · start 2006-11

    Registered record
    Registry ID
    NCT00408408
    Conditions
    Breast Cancer
    Interventions
    bevacizumab; capecitabine; cyclophosphamide; docetaxel; doxorubicin hydrochloride (Adriamycin); gemcitabine hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2006-11
    Completion
    2018-03
    Enrolment
    1,206

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventionbevacizumab; capecitabine; cyclophosphamide; docetaxel +2 more
    PhasePhase 3
    Registry statusUnknown

  • Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic Cancer

    NCT00426127 · start 2006-11

    Registered record
    Registry ID
    NCT00426127
    Conditions
    Pancreatic Cancer
    Interventions
    Docetaxel; Liposomal Doxorubicin; Enoxaparin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2006-11
    Completion
    2009-08
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Cancer
    InterventionDocetaxel; Liposomal Doxorubicin; Enoxaparin
    PhasePhase 2
    Registry statusTerminated